Aurinia Pharmaceuticals AUPH Debt Securities, Current
Debt Securities, Current at other companies
Other financials
Where this comes from
Reported directly by Aurinia Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:DebtSecuritiesCurrent.
The official record: Aurinia Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Aurinia Pharmaceuticals's debt securities, current.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Aurinia Pharmaceuticals's debt securities, current?
- Aurinia Pharmaceuticals (AUPH) reported debt securities, current of $337.78M in Q1 2026.
- How has Aurinia Pharmaceuticals's debt securities, current changed year-over-year?
- Aurinia Pharmaceuticals's debt securities, current increased by 37.0% year-over-year, from $246.47M to $337.78M.
- What is the long-term trend for Aurinia Pharmaceuticals's debt securities, current?
- Over 5 years (2020 to 2025), Aurinia Pharmaceuticals's debt securities, current has grown at a 20.3% compound annual growth rate (CAGR), from $125.98M to $317.78M.
- What does debt securities, current mean?
- This represents the portion of debt security investments held by the company that are expected to be realized or matured within one year. It reflects the firm's strategy for managing excess cash through short-term, interest-bearing financial instruments. Monitoring this balance helps investors assess the company's liquidity position and its approach to short-term capital preservation.